Prana Therapies Announces Positive Phase 1 Results for PRA-216, a Novel IL-4Rα/TSLP Bispecific Antibody, Supporting Its Potential Best-in-Disease Profile and Providing the First Clinical Validation of Prana’s INSPIRE Multispecific PlatformSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced positive Phase 1 results for PRA-216, its lead clinical program and a fully human, half-life-extended bispecific antibody developed on Prana’s proprietary INSPIRE platform. PRA-216 targets IL-4Rα and TSLP, combining broad downstream blockade of IL-4/IL-13 signaling with upstream TSLP inhibition to address complementary drivers of inflammation. The Phase 1 data were presented at the European Respiratory Society (ERS) International Congress 2026 in Barcelona, Spain (Late Breaker Poster #5809).
